1	Please	please	UH	_	2	intj	2:AM-DIS
2	enter	enter	VB	pb=enter.01	0	root	_
3	your	your	PRP$	_	4	poss	_
4	username	username	NN	_	2	dobj	2:A1=LOC
5	or	or	CC	_	4	cc	_
6	email	email	NN	_	7	nn	_
7	address	address	NN	_	4	conj	8:A1
8	provided	provided	VBN	pb=provide.01	7	partmod	_
9	during	during	IN	_	8	prep	8:AM-TMP
10	registration	registration	NN	_	9	pobj	_
11	.	.	.	_	2	punct	_

1	If	if	IN	_	7	mark	_
2	your	your	PRP$	_	3	poss	_
3	username	username	NN	_	7	nsubj	7:A1=PAG
4	or	or	CC	_	3	cc	_
5	email	email	NN	_	6	nn	_
6	address	address	NN	_	3	conj	_
7	exist	exist	VBP	p2=VB|pb=exist.01	14	advcl	14:AM-ADV
8	in	in	IN	_	7	prep	7:AM-LOC
9	our	our	PRP$	_	10	poss	_
10	database	database	NN	_	8	pobj	_
11	,	,	,	_	14	punct	_
12	you	you	PRP	_	14	nsubj	14:A0=PAG
13	will	will	MD	_	14	aux	14:AM-MOD
14	receive	receive	VB	pb=receive.01	0	root	_
15	instructions	instruction	NNS	_	14	dobj	14:A1=PPT
16	how	how	WRB	_	18	advmod	18:R-AM-MNR
17	to	to	TO	_	18	aux	_
18	reset	reset	VB	pb=reset.01	15	infmod	_
19	your	your	PRP$	_	20	poss	_
20	password	password	NN	_	18	dobj	18:A1=PPT
21	.	.	.	_	14	punct	_

1	WASHINGTON	washington	NNP	_	22	nsubj	22:A0=PAG
2	,	,	,	_	1	punct	_
3	DC	dc	NNP	_	5	hmod	_
4	-	-	HYPH	p2=,	5	hyph	_
5	A	a	NNP	p2=DT	6	nn	_
6	series	series	NN	_	1	appos	10:A1=PRD
7	of	of	IN	_	6	prep	_
8	research	research	NN	_	9	nn	_
9	articles	article	NNS	_	7	pobj	_
10	published	publish	VBN	p2=VBD|pb=publish.01	6	partmod	_
11	ahead	ahead	RB	_	10	advmod	10:AM-TMP
12	of	of	IN	_	11	prep	_
13	print	print	NN	_	12	pobj	_
14	in	in	IN	_	13	prep	_
15	the	the	DT	_	16	det	_
16	journal	journal	NN	_	14	pobj	_
17	Antimicrobial	antimicrobial	NNP	p2=JJ	18	nn	_
18	Agents	agent	NNPS	p2=NNS	16	appos	_
19	and	and	CC	_	18	cc	_
20	Chemotherapy	chemotherapy	NNP	p2=NNPS	18	conj	_
21	have	have	VBP	_	22	aux	_
22	identified	identify	VBN	pb=identify.01	0	root	_
23	a	a	DT	_	24	det	_
24	number	number	NN	_	22	dobj	35:A0=PAG;22:A1=PPT
25	of	of	IN	_	24	prep	_
26	existing	exist	VBG	p2=JJ|pb=exist.01	28	amod	_
27	pharmaceutical	pharmaceutical	JJ	p2=NN	28	amod	_
28	drugs	drug	NNS	_	25	pobj	26:A1=PAG
29	and	and	CC	_	28	cc	_
30	compounds	compound	NNS	_	28	conj	_
31	under	under	IN	_	24	prep	_
32	development	development	NN	_	31	pobj	_
33	that	that	WDT	_	35	nsubj	35:R-A0
34	may	may	MD	_	35	aux	35:AM-MOD
35	offer	offer	VB	pb=offer.01	24	rcmod	_
36	effective	effective	JJ	_	37	amod	_
37	therapies	therapy	NNS	_	35	dobj	35:A1=PPT
38	against	against	IN	_	35	prep	_
39	Middle	middle	NNP	_	40	nn	_
40	East	east	NNP	_	42	nn	_
41	Respiratory	respiratory	NNP	_	42	nn	_
42	Syndrome	syndrome	NNP	_	38	pobj	_
43	(	(	-LRB-	_	42	punct	_
44	MERS	mers	NNP	_	42	appos	_
45	)	)	-RRB-	_	42	punct	_
46	.	.	.	_	22	punct	_

1	In	in	IN	_	7	prep	7:AM-LOC
2	the	the	DT	_	4	det	_
3	first	#ord#	JJ	_	4	amod	_
4	study	study	NN	_	1	pobj	_
5	,	,	,	_	7	punct	_
6	researchers	researcher	NNS	_	7	nsubj	7:A0=PAG
7	screened	screen	VBD	p2=VBP|pb=screen.02	0	root	_
8	a	a	DT	_	9	det	_
9	library	library	NN	_	7	dobj	7:A1=PPT
10	of	of	IN	_	9	prep	_
11	290	0	CD	_	13	num	_
12	pharmaceutical	pharmaceutical	JJ	p2=NN	13	amod	_
13	drugs	drug	NNS	_	10	pobj	_
14	,	,	,	_	7	punct	_
15	either	either	CC	_	18	preconj	_
16	FDA	fda	NNP	_	18	hmod	_
17	-	-	HYPH	_	18	hyph	_
18	approved	approve	VBN	_	7	conj	_
19	or	or	CC	_	18	cc	_
20	in	in	IN	_	18	conj	_
21	advanced	advanced	JJ	_	23	amod	_
22	clinical	clinical	JJ	_	23	amod	_
23	development	development	NN	_	20	pobj	_
24	for	for	IN	_	23	prep	_
25	antiviral	antiviral	JJ	_	26	amod	_
26	activity	activity	NN	_	24	pobj	_
27	against	against	IN	_	26	prep	_
28	the	the	DT	_	30	det	_
29	MERS	mers	NNP	p2=NNS	30	nn	_
30	coronavirus	coronavirus	NN	p2=NNP	27	pobj	_
31	(	(	-LRB-	_	34	punct	_
32	MERS	mers	NNP	p2=NNS	34	hmod	_
33	-	-	HYPH	p2=:	34	hyph	_
34	CoV	cov	NNP	_	30	appos	_
35	)	)	-RRB-	_	34	punct	_
36	and	and	CC	_	30	cc	_
37	severe	severe	JJ	p2=VB	41	amod	_
38	acute	acute	JJ	_	41	amod	_
39	respiratory	respiratory	JJ	_	40	nn	_
40	syndrome	syndrome	NN	_	41	nn	_
41	coronavirus	coronavirus	NNS	p2=NN	13	appos	_
42	(	(	-LRB-	_	45	punct	_
43	SARS	sars	NNP	_	45	hmod	_
44	-	-	HYPH	p2=:	45	hyph	_
45	CoV	cov	NNP	_	41	appos	_
46	)	)	-RRB-	_	45	punct	_
47	in	in	IN	_	41	prep	_
48	cell	cell	NN	_	49	nn	_
49	culture	culture	NN	_	47	pobj	_
50	.	.	.	_	7	punct	_

1	They	they	PRP	_	2	nsubj	2:A0=PAG
2	found	find	VBD	pb=find.01	0	root	_
3	27	0	CD	_	4	num	_
4	compounds	compound	NNS	_	2	dobj	2:A1=PPT;6:A1=PPT
5	that	that	WDT	_	6	nsubj	6:R-A1
6	were	be	VBD	pb=be.01	4	rcmod	_
7	active	active	JJ	_	6	acomp	6:A2=PRD
8	against	against	IN	_	7	prep	_
9	both	both	DT	_	10	det	_
10	viruses	virus	NNS	_	8	pobj	_
11	including	include	VBG	_	10	prep	_
12	some	some	DT	_	14	det	_
13	cancer	cancer	NN	_	14	nn	_
14	drugs	drug	NNS	_	11	pobj	_
15	and	and	CC	_	14	cc	_
16	antipsychotics	antipsychotic	NNS	p2=NN	14	conj	_
17	.	.	.	_	2	punct	_

1	In	in	IN	_	7	prep	7:AM-LOC
2	the	the	DT	_	4	det	_
3	second	#ord#	JJ	_	4	amod	_
4	study	study	NN	_	1	pobj	_
5	,	,	,	_	7	punct	_
6	researchers	researcher	NNS	_	7	nsubj	7:A0=PAG
7	collaborating	collaborate	VBG	pb=collaborate.01	0	root	_
8	in	in	IN	_	7	prep	_
9	the	the	DT	_	13	det	_
10	European	european	JJ	_	13	amod	_
11	antiviral	antiviral	JJ	_	13	amod	_
12	research	research	NN	_	13	nn	_
13	program	program	NN	_	8	pobj	_
14	SILVER	silver	NNP	p2=NN	18	nsubj	18:A0=PAG;23:A0=PAG
15	(	(	-LRB-	_	14	punct	_
16	www.silver-europe.com	#url#	ADD	_	14	appos	_
17	)	)	-RRB-	_	14	punct	_
18	used	use	VBD	pb=use.01	7	ccomp	7:A1=COM
19	a	a	DT	_	21	det	_
20	similar	similar	JJ	_	21	amod	_
21	methodology	methodology	NN	_	18	dobj	18:A1=PPT
22	to	to	TO	_	23	aux	_
23	screen	screen	VB	pb=screen.03	18	xcomp	18:A2=PRP
24	a	a	DT	_	25	det	_
25	library	library	NN	_	23	dobj	23:A1=PPT
26	of	of	IN	_	25	prep	_
27	348	0	CD	_	31	num	_
28	FDA	fda	NNP	_	30	hmod	_
29	-	-	HYPH	_	30	hyph	_
30	approved	approve	VBN	_	31	amod	_
31	drugs	drug	NNS	_	26	pobj	_
32	for	for	IN	_	25	prep	_
33	anti-MERS-CoV	anti-mers-cov	JJ	p2=NN	34	amod	_
34	activity	activity	NN	_	32	pobj	_
35	in	in	IN	_	34	prep	_
36	cell	cell	NN	_	37	nn	_
37	culture	culture	NN	_	35	pobj	_
38	.	.	.	_	7	punct	_

1	They	they	PRP	_	2	nsubj	2:A0=PAG
2	identified	identify	VBD	pb=identify.01	0	root	_
3	four	#crd#	CD	_	4	num	_
4	compounds	compound	NNS	_	2	dobj	6:A0=PAG;2:A1=PPT
5	that	that	WDT	p2=IN	6	nsubj	6:R-A0
6	inhibited	inhibit	VBD	p2=JJ|pb=inhibit.01	4	rcmod	_
7	MERS	mers	NNP	p2=NNS	9	hmod	_
8	-	-	HYPH	_	9	hyph	_
9	CoV	cov	NNP	_	6	dobj	6:A1=PPT
10	,	,	,	_	9	punct	_
11	SARS	sars	NNP	_	13	hmod	_
12	-	-	HYPH	_	13	hyph	_
13	CoV	cov	NNP	_	9	conj	_
14	and	and	CC	_	13	cc	_
15	Human	human	NNP	_	16	nn	_
16	Coronavirus	coronavirus	NNP	_	17	nn	_
17	229E	229e	NNP	p2=CD	13	conj	_
18	at	at	IN	_	6	prep	_
19	relatively	relatively	RB	_	20	advmod	_
20	low	low	JJ	_	21	amod	_
21	concentrations	concentration	NNS	_	18	pobj	_
22	.	.	.	_	2	punct	_

1	Two	#crd#	CD	_	7	nsubjpass	7:A1=PPT
2	of	of	IN	_	1	prep	_
3	the	the	DT	_	4	det	_
4	compounds	compound	NNS	p2=NNPS	2	pobj	_
5	were	be	VBD	_	7	auxpass	_
6	also	also	RB	_	7	advmod	7:AM-ADV
7	identified	identify	VBN	pb=identify.01	0	root	_
8	by	by	IN	_	7	agent	7:A0=PAG
9	the	the	DT	_	11	det	_
10	U.S.	u.s.	NNP	_	11	nn	_
11	study	study	NN	_	8	pobj	_
12	:	:	:	_	11	punct	_
13	the	the	DT	_	16	det	_
14	antimalarial	antimalarial	JJ	p2=NN	16	amod	_
15	drug	drug	NN	_	16	nn	_
16	chloroquine	chloroquine	NN	p2=RB	11	appos	_
17	and	and	CC	_	16	cc	_
18	the	the	DT	_	20	det	_
19	antipsychotic	antipsychotic	JJ	_	20	amod	_
20	chlorpromazine	chlorpromazine	NN	_	16	conj	_
21	.	.	.	_	7	punct	_

1	"	"	``	_	23	punct	_
2	Although	although	IN	_	12	mark	_
3	their	their	PRP$	_	5	poss	_
4	therapeutic	therapeutic	JJ	_	5	amod	_
5	potential	potential	NN	p2=JJ	12	nsubj	12:A1=PPT;15:A1=PPT
6	(	(	-LRB-	_	5	punct	_
7	alone	alone	RB	p2=JJ	9	advmod	_
8	or	or	CC	_	9	cc	_
9	in	in	IN	_	5	prep	_
10	combination	combination	NN	_	9	pobj	_
11	)	)	-RRB-	_	5	punct	_
12	remains	remain	VBZ	pb=remain.01	23	advcl	23:AM-ADV
13	to	to	TO	_	15	aux	_
14	be	be	VB	_	15	auxpass	_
15	assessed	assess	VBN	pb=assess.01	12	xcomp	12:A3=PRD
16	in	in	IN	_	15	prep	15:AM-LOC
17	animal	animal	NN	_	18	nn	_
18	models	model	NNS	_	16	pobj	_
19	,	,	,	_	23	punct	_
20	our	our	PRP$	_	21	poss	_
21	findings	finding	NNS	_	23	nsubj	23:A0=PAG
22	may	may	MD	_	23	aux	23:AM-MOD
23	offer	offer	VB	pb=offer.01	41	ccomp	41:A1=PPT
24	a	a	DT	_	26	det	_
25	starting	starting	NN	p2=JJ	26	nn	_
26	point	point	NN	_	23	dobj	23:A1=PPT
27	for	for	IN	_	26	prep	_
28	treatment	treatment	NN	_	27	pobj	_
29	of	of	IN	_	28	prep	_
30	patients	patient	NNS	_	29	pobj	31:A1=GOL
31	infected	infect	VBN	pb=infect.01	30	partmod	_
32	with	with	IN	_	31	prep	31:A2=PPT
33	zoonotic	zoonotic	JJ	p2=NN	34	amod	_
34	coronaviruses	coronavirus	NNS	_	32	pobj	_
35	like	like	IN	p2=VBP	34	prep	_
36	MERS	mers	NNP	p2=NNS	38	hmod	_
37	-	-	HYPH	p2=:	38	hyph	_
38	CoV	cov	NNP	_	35	pobj	_
39	,	,	,	_	41	punct	_
40	"	"	''	_	41	punct	_
41	says	say	VBZ	pb=say.01	0	root	_
42	corresponding	correspond	VBG	p2=JJ|pb=correspond.02	43	amod	_
43	author	author	NN	_	45	nn	42:A1=PPT
44	Eric	eric	NNP	_	45	nn	_
45	Snijder	snijder	NNP	_	41	nsubj	41:A0
46	of	of	IN	_	45	prep	_
47	Leiden	leiden	NNP	_	48	nn	_
48	University	university	NNP	_	50	nn	_
49	Medical	medical	NNP	_	50	nn	_
50	Center	center	NNP	_	46	pobj	_
51	,	,	,	_	50	punct	_
52	the	the	DT	_	53	det	_
53	Netherlands	netherlands	NNP	_	50	appos	_
54	.	.	.	_	41	punct	_

1	Researchers	researcher	NNS	_	25	advcl	25:AM-ADV
2	from	from	IN	_	1	prep	_
3	the	the	DT	_	5	det	_
4	Rega	rega	NNP	_	5	nn	_
5	Institute	institute	NNP	_	2	pobj	_
6	for	for	IN	_	5	prep	_
7	Medical	medical	NNP	_	8	nn	_
8	Research	research	NNP	_	6	pobj	_
9	in	in	IN	_	5	prep	_
10	Leuven	leuven	NNP	_	9	pobj	_
11	,	,	,	_	10	punct	_
12	Belgium	belgium	NNP	_	10	conj	_
13	and	and	CC	_	12	cc	_
14	the	the	DT	_	17	det	_
15	Erasmus	erasmus	NNP	_	17	nn	_
16	Medical	medical	NNP	_	17	nn	_
17	Center	center	NNP	_	12	conj	_
18	in	in	IN	_	17	prep	_
19	Rotterdam	rotterdam	NNP	_	18	pobj	_
20	,	,	,	_	25	punct	_
21	the	the	DT	_	22	det	_
22	Netherlands	netherlands	NNP	p2=NNPS	25	nsubjpass	25:A1=PPT
23	were	be	VBD	_	25	auxpass	_
24	also	also	RB	_	25	advmod	25:AM-DIS
25	involved	involve	VBN	pb=involve.01	0	root	_
26	in	in	IN	_	25	prep	25:A2=PPT
27	the	the	DT	_	28	det	_
28	study	study	NN	_	26	pobj	_
29	.	.	.	_	25	punct	_

1	The	the	DT	_	5	det	_
2	third	#ord#	JJ	_	5	amod	_
3	and	and	CC	_	2	cc	_
4	final	final	JJ	_	2	conj	_
5	study	study	NN	_	6	nsubj	6:A0=PAG
6	finds	find	VBZ	pb=find.01	0	root	_
7	that	that	IN	_	22	complm	_
8	an	an	DT	_	10	det	_
9	experimental	experimental	JJ	_	10	amod	_
10	compound	compound	NN	_	22	nsubj	22:A0=PAG
11	,	,	,	_	10	punct	_
12	previously	previously	RB	_	13	advmod	13:AM-TMP
13	shown	show	VBN	pb=show.01	10	partmod	_
14	to	to	TO	p2=IN	15	aux	_
15	block	block	VB	pb=block.01	13	xcomp	13:A1=PPT
16	SARS	sars	NNP	_	18	hmod	_
17	-	-	HYPH	p2=:	18	hyph	_
18	CoV	cov	NNP	_	19	nn	_
19	replication	replication	NN	p2=NNP	15	dobj	15:A1
20	,	,	,	_	22	punct	_
21	can	can	MD	_	22	aux	22:AM-MOD
22	inhibit	inhibit	VB	pb=inhibit.01	6	ccomp	6:A1=PPT
23	replication	replication	NN	_	22	dobj	22:A1=PPT
24	of	of	IN	_	23	prep	_
25	two	#crd#	CD	_	27	num	_
26	other	other	JJ	_	27	amod	_
27	coronaviruses	coronavirus	NNS	_	24	pobj	_
28	,	,	,	_	27	punct	_
29	MERS	mers	NNP	p2=NNS	31	hmod	_
30	-	-	HYPH	_	31	hyph	_
31	CoV	cov	NNP	_	27	appos	_
32	and	and	CC	_	31	cc	_
33	mouse	mouse	NN	p2=NNP	34	nn	_
34	hepatitis	hepatitis	NN	_	35	nn	_
35	virus	virus	NN	_	31	conj	_
36	.	.	.	_	6	punct	_

1	Antimicrobial	antimicrobial	JJ	p2=AFX	2	amod	_
2	Agents	agent	NNS	p2=NNPS	5	dep	_
3	and	and	CC	_	2	cc	_
4	Chemotherapy	chemotherapy	NNP	p2=NN	5	nsubj	5:A1=PPT
5	is	be	VBZ	pb=be.01	0	root	_
6	a	a	DT	_	7	det	_
7	publication	publication	NN	_	5	attr	5:A2=PRD
8	of	of	IN	_	7	prep	_
9	the	the	DT	_	11	det	_
10	American	american	NNP	p2=JJ	11	nn	_
11	Society	society	NNP	_	8	pobj	_
12	for	for	IN	_	11	prep	_
13	Microbiology	microbiology	NNP	_	12	pobj	_
14	(	(	-LRB-	_	11	punct	_
15	ASM	asm	NNP	_	11	appos	_
16	)	)	-RRB-	_	11	punct	_
17	.	.	.	_	5	punct	_

1	 	 	:	p2=NFP	4	punct	_
2	The	the	DT	_	3	det	_
3	ASM	asm	NNP	p2=NN	4	nsubj	4:A1=PPT
4	is	be	VBZ	pb=be.01	0	root	_
5	the	the	DT	_	10	det	_
6	largest	large	JJS	_	10	amod	_
7	single	single	JJ	_	8	amod	_
8	life	life	NN	_	10	nn	_
9	science	science	NN	_	10	nn	_
10	society	society	NN	_	4	attr	12:A1=PRD;4:A2=PRD
11	,	,	,	_	10	punct	_
12	composed	compose	VBN	pb=compose.01	10	partmod	_
13	of	of	IN	_	12	prep	12:A2=VSP
14	over	over	IN	p2=RB	15	quantmod	_
15	39,000	0	CD	_	16	num	_
16	scientists	scientist	NNS	_	13	pobj	_
17	and	and	CC	_	16	cc	_
18	health	health	NN	_	19	nn	_
19	professionals	professional	NNS	_	16	conj	_
20	.	.	.	_	4	punct	_

1	Its	its	PRP$	_	2	poss	_
2	mission	mission	NN	_	3	nsubj	3:A1=PPT
3	is	be	VBZ	pb=be.01	0	root	_
4	to	to	TO	_	5	aux	_
5	advance	advance	VB	pb=advance.01	3	xcomp	3:A2=PRD
6	the	the	DT	_	8	det	_
7	microbiological	microbiological	JJ	p2=NN	8	amod	_
8	sciences	science	NNS	_	5	dobj	5:A1=PPT
9	as	as	IN	_	5	prep	5:AM-PRD
10	a	a	DT	_	11	det	_
11	vehicle	vehicle	NN	_	9	pobj	_
12	for	for	IN	_	11	prep	_
13	understanding	understand	VBG	p2=NN|pb=understand.01	12	pcomp	_
14	life	life	NN	_	15	nn	_
15	processes	process	NNS	_	13	dobj	13:A1=PPT
16	and	and	CC	_	5	cc	_
17	to	to	TO	_	18	aux	_
18	apply	apply	VB	pb=apply.01	5	conj	_
19	and	and	CC	_	18	cc	_
20	communicate	communicate	VB	pb=communicate.01	18	conj	_
21	this	this	DT	_	22	det	_
22	knowledge	knowledge	NN	_	20	dobj	20:A1=PPT
23	for	for	IN	_	20	prep	20:A2=COM
24	the	the	DT	_	25	det	_
25	improvement	improvement	NN	_	23	pobj	_
26	of	of	IN	_	25	prep	_
27	health	health	NN	_	26	pobj	_
28	and	and	CC	_	27	cc	_
29	environmental	environmental	JJ	_	34	amod	_
30	and	and	CC	_	29	cc	_
31	economic	economic	JJ	_	29	conj	_
32	well	well	NN	p2=RB	34	hmod	_
33	-	-	HYPH	p2=:	34	hyph	_
34	being	being	NN	p2=VBG	27	conj	_
35	worldwide	worldwide	RB	_	34	advmod	_
36	.	.	.	_	3	punct	_

